tbuckley/cabot-search huggingface dataset:
Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms
Authors: Monika M Kutyna, Chung Hoow Kok, Sharon Paton, Dimitrios Cakouros, Agnieszka Arthur, Timothy P. Hughes, Daniel Thomas, David Campbell, Stan Gronthos, Devendra Hiwase
Journal: Blood (2021)
The Association between Clonal Hematopoiesis and Gout
Authors: Mridul Agrawal, Abhishek Niroula, Pierre Cunin, Marie McConkey, Peter G. Kim, Waihay J. Wong, Lachelle D. Weeks, Amy E. Lin, Peter G. Miller, Christopher J. Gibson, Aswin Sekar, Donna S. Neuberg, Alexander G. Bick, Pradeep Natarajan, Peter A. Nigrovic, Deepak A. Rao, Benjamin L. Ebert
Journal: Blood (2021)
Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis
Authors: Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D. Bledsoe, Naval Daver, Elias J. Jabbour, Tapan M. Kadia, Zeev E. Estrov, Steven M. Kornblau, Michael Andreeff, Jorge E. Cortes, Nitin Jain, Gautam Borthakur, Yesid Alvarado, Julie Huynh-Lu, Madeleine M. Nguyen-Cao, Mary Ann Richie, Mackenzie H. Dobbins, Selene Andrea McCrackin, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2021)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy
Authors: Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood (2021)
Novel Germline <i>POT1</i> Variant Predisposes to Childhood Acute Myeloid Leukemia
Authors: Pia Michler, Franziska Auer, Rabea Wagener, Triantafyllia Brozou, Ulrike Anne Friedrich, Carolin Walter, Martin Dugas, Arndt Borkhardt, Friedrich Stölzel, Julia Hauer
Journal: Blood (2021)
Abstract 20898: The Value of Sensing Optimization During Exercise After S-ICD Implantation
Authors: Kirsten M Kooiman, Sarah W Baalman, Tom F Brouwer, Anne Floor B Quast, Reinoud E Knops
Journal: Circulation (2017)

Introduction: T-wave oversensing (TWOS) is the main cause of inappropriate shocks (IAS) in patients with a subcutaneous ICD (S-ICD). Sensing optimization during exercise post S-ICD implantation may prevent IAS caused by TWOS. In our tertiary center, sensing optimization after S-ICD implantation has been used as standard of care since 2014. Improved detection and sensing algorithms, like high pass filter designs, are expected to overcome the problem of TWOS, but the value of sensing optimization during exercise is unknown. Hypothesis: Sensing optimization during exercise prevents TWOS-related IAS in patients implanted with an S-ICD. Methods: Sensing optimization was performed within two months in all patients who underwent S-ICD implantation or replacement. Sensing was evaluated during maximal exercise and a new QRS morphology template was stored. The optimal sensing vector was determined based on absence of TWOS and optimal R-T ratio. Follow-up data on IAS was divided into a group before and a group after introduction of the high pass filter, and compared with data of S-ICD patients and IAS in our institution before 2014. Results: We analyzed 65 patients (69% male, mean age 45 years, ischemic cardiomyopathy in 25%, genetic arrhythmia disease in 37%). Mean maximal heart rate (maxHR) was 142 bpm. A new template was stored in 61 patients (94%). TWOS was observed in 12 patient (18%), but not in the programmed sensing vector selected by the post implant automatic setup. The sensing vector was changed in nine patients (14%) (mean age 35 years, maxHR 163 bpm) based on drop in QRS amplitude in five patients, variable QRS amplitudes in two, an inferior R-T ratio in one and sensing of myopotentials in one. The IAS incidence caused by TWOS declined from 11.6% in 2012 to 2.0% and 0% before and after the introduction of the high pass filter, respectively. Conclusions: There is a decrease in TWOS-related IAS. Sensing optimization during exercise may be an additional tool to overcome TWOS-related IAS in S-ICD patients. Future studies may identify patients, such as those capable of reaching high heart rates, who are most likely to benefit from sensing optimization during exercise.
Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Authors: Xavier Andrade-Gonzalez, Raphael Mwangi, Jithma P. Abeykoon, Paul J. Hampel, Saurabh Zanwar, Betsy Laplant, Gita Thanarajasingam, Umar Farooq, Matthew J. Maurer, Thomas E. Witzig, Thomas M. Habermann, Jose C. Villasboas, Anne J. Novak
Journal: Blood (2021)
'Application of Prognostic Scoring in Systemic Mastocytosis Patients within a UK Centre of Excellence: Guys and St Thomas' NHS Foundation Trust.'
Authors: Priya Sriskandarajah, Clare Oni, Claire Woodley, Susan Asirvatham, Monika Ciesielska, Chienye Asinobi, Rebecca Todd, Natalia Curto-Garcia, Jennifer O'Sullivan, Chandan Saha, Thompson Olaoni, Anna Green, Yurina Miki, Mark Ong, Donal P McLornan, Claire N. Harrison, Clive Grattan, Deepti H. Radia
Journal: Blood (2021)
Premedication with Hydrocortisone Increases Risk of Adverse Drug Events and Return to Medical Care Among Pediatric Patients with ITP Treated with IVIG
Authors: Megan M Gilbert, Taylor Olmsted Kim, Susan E Kirk, Hyojeong Han, Xiaofan Huang, Kristen A Staggers, Rachael F. Grace, Cindy Neunert, Michele P. Lambert, Jenny M. Despotovic, Amanda B Grimes
Journal: Blood (2021)
Predictors of Central Nervous System (CNS) Involvement in North American Adult T-Cell Leukemia Lymphoma (ATLL) and Their Survival Pattern
Authors: Riya Patel, Shafia Rahman, Nishi Shah, Astha Thakkar, Ana Acuna-Villaorduna, Urvi A Shah, Diego Adrianzen Herrera, Alyssa De Castro, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Latoya Townsend Nugent, Yanhua Wang, Olga Derman, Shira Slasky, Kira Gritsman, Ulrich G. Steidl, Mendel Goldfinger, Noah Kornblum, Aditi Shastri, Ioannis Mantzaris, Lizamarie Bachier-Rodriguez, Ira Braunschweig, Amit Verma, Katharine McNeill, B. Hilda Ye, Murali Janakiram, R. Alejandro Sica
Journal: Blood (2021)
Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Authors: Sigurdur Y Kristinsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Elin Ruth Reed, Jon Thorir Thorir Oskarsson, Iris Petursdottir, Gudrun Asta Sigurdardottir, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Signy Vala Sveinsdottir, Robert Palmason, Isleifur Olafsson, Fridbjorn Sigurdsson, Asdis Rosa Thordardottir, Elias Eythorsson, Asbjorn Jonsson, Runolfur Palsson, Olafur Skuli Indridason, Gauti Kjartan Gislason, Andri Olafsson, Jon Kristinn Sigurdsson, Ingigerdur Solveig Sverrisdottir, Maria Soffia Juliusdottir, Gudlaug Katrin Hakonardottir, Hlif Steingrimsdottir, Ragnar Danielsen, Petros Kampanis, Malin Hultcrantz, Brian G.M. Durie, Stephen Harding, Ola Landgren, Thorvardur Jon Love
Journal: Blood (2021)
E.coli Nissle increases transcription of flagella assembly and formate hydrogenlyase genes in response to colitis
Authors: Louis C Dacquay, Derek Tsang, Donny Chan, John Parkinson, Dana J Philpott, David R McMillen
Journal: Gut Microbes (2021)

Escherichia coli Nissle (EcN), a probiotic bacterium, has been employed in treating inflammatory bowel disease, but the nature of its therapeutic effect is not fully understood. Intestinal inflammation alters the environment, exposing the microbial population to new stresses and eliciting transcriptional responses. We administered EcN to germ-free mice and then compared its transcriptional response between DSS-treated and untreated conditions using RNA-seq analysis to identify 187 differentially expressed genes (119 upregulated, 68 downregulated) and verifying a subset with qRT-PCR. The upregulated genes included many involved in flagella biosynthesis and motility, as well as several members of the formate hydrogenlyase complex. Despite prior evidence that these pathways are both transcriptionally regulated by nitric oxide, in vitro tests did not establish that nitric oxide exposure alone elicited the transcriptional response. The results provide new information on the transcriptional response of EcN to inflammation and establish a basis for further investigation of its anti-inflammatory activity.
Implication of ICOSLG on Relapse in Infant T(4;11) Acute Lymphoblastic Leukemia
Authors: Marius Külp, Anna Lena Siemund, Claus Meyer, Patrizia Larghero, Alissa Dietz, Julia Alten, Gunnar Cario, Aurélie Caye-Eude, Hélène Cavé, Michela Bardini, Paola De Lorenzo, Giovanni Cazzaniga, Laura Diehl, Halvard Bonig, Rolf Marschalek
Journal: Blood (2021)
Abstract 9051: Gender Differences and Aging on Beta-Adrenergic Receptor Subtypes Expression and Function in Murine Left Ventricular Myocytes
Authors: Che Ping Cheng, Zhe Chen, Jing Cao, Xiaoqiang Sun, Peng Zhou, David Zhao, David M Herrington, Dalane W Kitzman, Heng Cheng
Journal: Circulation (2021)

Background: Sex-specific modulation of β-adrenergic receptor (AR) stimulation plays a pivotal role in cardiac function and in the manifestation of heart disease, including aging. However, the sex and age influences on 3 cardiac β-AR subtypes have not been systematically evaluated. Their effects on β 1 -AR have yielded mixed results. Virtually no previous studies have examined sex and age-related changes on the functional cardiac β 3 -AR. We hypothesized that sex differences exist in aging-induced changes in myocyte β 1 - and β 3 -AR. Aged males may exhibit a greater selective β 1 -AR downregulation with a more pronounced decline of β-AR reserve. Methods: LV myocytes were obtained from young (Y) (6 mo) and aged (A) (24 mo) (6/group) male (M) and female (F) wild-type mice. We simultaneously compared LV myocyte protein levels of β 1 -, β 2 -, and β 3 -AR, and the responses of cell contractile function (dL/dt max ) to β-AR subtype stimulation by random exposure of myocytes to isoproterenol (ISO) (10 -8 M) or a selective β 1 -, β 2 -, or β 3 -agonist, Norepinephrine (NE, 10 -7 M), Zinterol (ZIN,10 -5 M) and BRL-37,344 (BRL,10 -8 M), respectively. Results: In Y mice, no sex differences were found in myocyte protein levels of β 1 - (YM: 0.73 vs YF: 0.74), β 2 - (0.28 vs 0.29) and β 3 -AR (0.19 vs 0.17). Consistently, there were similarly significant increases in dL/dt max in responses to ISO (YM: 73%, 209.5 vs121.1; YF: 72%, 210.7 vs122.5 μm/s), NE (48% vs 45%), ZIN (18% vs 20%) and decrease after BRL (8.1% vs 7.9%). Compared with sex-matched Y, in both AM and AF, aging caused a ~58% significant increase in β 3 (AM: 0.30 vs AF: 0.27) and slightly reduced β 2 (11% vs 6%) (P=NS). Aging caused ~30% decline in basal cell contractility. No sex differences in dL/dt max of aging myocyte response to ZIN (increased AM: 17% vs AF: 20%), and BRL (decreased 19% vs 21%). However, in AM, β 1 decreased 33% (0.48) which was significantly greater than that in AF (26%, 0.55). Versus AF, in AM, ISO caused significantly less increase in dL/dt max (34% vs 48%) accompanied by attenuated NE-mediated increase in dL/dt max (17% vs 26%). Conclusions: Aging is associated with LV myocyte β 1 -AR downregulation and β 3 -AR upregulation. Sex affects age-related β 1 -AR downregulation, with males exhibiting a more profound decrease with increasing age.
Abstract 10927: Development and Psychometric Testing of A Heart-Healthy Information Questionnaire
Authors: Jina Choo, Jihyun Moon, Songwhi Noh, Yura Shin
Journal: Circulation (2021)

Introduction: Acquiring sufficient information about cardiovascular prevention is a prerequisite for individuals’ decision making to practice heart-healthy lifestyle behaviors. However, no well-validated instrument currently exists to measure the knowledge about information on heart disease symptoms, risk factors, and benefits of heart-healthy behaviors for cardiovascular prevention targeting healthy people. We used systematic scale development procedures to create a scale of the Heart-Healthy Information Questionnaire (HHIQ) based on the Information-Motivation-Behavioral skills model and recent scientific guidelines of cardiovascular prevention. Methods: Standard scale development methods were used to create items and test their psychometric properties. Participants were 1,315 people without cardiovascular diseases, who were residing in Seoul Metropolitan city. Results: We created preliminary 70 items using a 3-point True/False format with a Don’t know option. The items were two times reviewed by a panel of eight experts in terms of the relevance and clarity of the items, and 54 items were selected by using the cut-off score of content validity index (0.8 or greater). Next, we administrated the questionnaire of 54 items for 1,315 participants, and finally selected 50 items by using the cut-off scores of difficulty index ( &lt; 0.95), discrimination index ( &gt; 10), and item-total correlation (tetrachoric coefficient &gt; 0.2). The Kuder-Richardson formula 20 coefficient for the HHIQ indicated good internal consistency (0.85), and the test-retest reliability coefficient with a 15-day interval also indicated that it had good stability (0.78). Finally, individuals (n = 107) who were informed from heart-healthy education sessions showed significantly higher scores of the HHIQ than those (n = 1,208) who were not informed (p = 0.009). A total score of the HHIQ was significantly correlated with a total score of the Heart Disease Facts Questionnaire (r = 0.61, p &lt; 0.001) and significantly correlated with a total score of the Evaluation Tool for Metabolic Syndrome Modification Lifestyles (r = 0.23, p &lt; 0.001). Conclusion: The HHIQ may be useful to evaluate the knowledge levels of heart-healthy information in the areas of cardiovascular prevention
Description of Major Osteoporotic Fractures in Women with Invasive Breast Cancer Who Received Endocrine Therapy
Authors: Joan C. Lo, Cecile A. Laurent, Janise M. Roh, Jean Lee, Malini Chandra, Song Yao, Marilyn L. Kwan
Journal: JAMA Network Open (2021)

a International Classification of Diseases, 9th Revision (ICD-9) codes were used to ascertain fracture diagnoses for clinical adjudication.Fracture adjudication was conducted by a physician with expertise in skeletal health supported by a medical records analyst.Incident fractures were identified by acute or subacute characteristics, evidence of ongoing fracture healing, or in the case of vertebral fracture, acute and subacute findings or clinical notes indicating an acute event, presentation, or clearly localizing symptoms.Pathologic (cancer-related) fractures were differentiated from nonpathologic fractures by imaging features, histopathology, evidence of osseous metastases, oncology physician assessment, or targeted treatment (eg, localized radiation therapy).Prevalent vertebral fractures were determined based on previous vertebral fracture history or incidental identification of vertebral fracture of indeterminant age in a patient without an acute event or clearly localizing symptoms.These included a few fractures occurring sometime after breast cancer diagnosis but were prevalent fractures when they were incidentally discovered.Fractures associated with hospitalized major trauma (ICD-9 E800-E848) were excluded.
First Year Comparison of Sickle Cell Pediatric Cohorts from Haiti and Miami (CSHSCD Multicenter Study): Baseline Data
Authors: Ofelia A. Alvarez, Nora St Victor Dely, Michele Paul-Hanna, Alejandro Mantero, Rony Saint Fleur, Tally Hustace, Emanise Muscadin, Paulonne Bien-Aime, Woodgina Mondesir, Mimose Voltaire, Ronald Eveillard, Eric R. Brown, Louis Herns Marcelin, Emmeline Lerebours
Journal: Blood (2021)
The oral microbiota and its role in carcinogenesis
Authors: Mark Stasiewicz, Tomasz M. Karpiński
Journal: Seminars in Cancer Biology (2021)

Despite decades of research, cancer continues to be a major global health concern. In recent years, the role played by microorganisms in the development and progression of cancer has come under increased scrutiny. The aim of the present review is to highlight the main associations between members of the human oral microbiota and various cancers. The PubMed database was searched for available literature to outline the current state of understanding regarding the role of the oral microbiota and a variety of human cancers. Oral squamous cell carcinoma (OSCC) is associated with carriage of a number of oral bacteria (e.g., Porphyromonas gingivalis, Fusobacterium nucleatum, Streptococcus sp.), certain viruses (e.g., human papilloma virus, human herpes virus 8, herpes simplex virus 1 and Epstein-Barr virus) and yeast (Candida albicans). Moreover, members of the oral microbiota are associated with cancers of the esophagus, stomach, pancreas, colon/rectum and lung. Furthermore, the present review outlines a number of the carcinogenic mechanisms underlying the presented microbial associations with cancer. Such information may one day help clinicians to diagnose neoplastic diseases at earlier stages and prescribe treatments that take into account the possible microbial nature of carcinogenesis.
Single-Cell Proteomics Identifies Leukemia Landscape Associated with Clinical Outcomes in R/R AML Treated with MDM2i (Milademetan) and FLT3i (Quizartinib): Putative Role of CD68 and Diversity Index
Authors: Muharrem Muftuoglu, Li Li, Mahesh Basyal, Shaoheng Liang, Carissa J. Ball, Ken Chen, Prasanna Kumar, Arnaud Lesegretain, Naval Daver, Michael Andreeff
Journal: Blood (2021)
The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
Authors: Ana Luiza Drumond-Bock, Magdalena Bieniasz
Journal: Molecular Cancer (2021)

Abstract High-grade serous ovarian carcinoma (HGSOC) is the most aggressive type of ovarian cancer, often diagnosed at advanced stages. Molecularly, HGSOC shows high degree of genomic instability associated with large number of genetic alterations. BRD4 is the 4th most amplified gene in HGSOC, which correlates with poor patients’ prognosis. BRD4 is constitutively expressed and generates two proteins, BRD4 long (BRD4-L) and BRD4 short (BRD4-S). Both isoforms contain bromodomains that bind to lysine-acetylated histones. Amongst other functions, BRD4 participates in chromatin organization, acetylation of histones, transcriptional control and DNA damage repair. In cancer patients with amplified BRD4 , the increased activity of BRD4 is associated with higher expression of oncogenes, such as MYC , NOTCH3 and NRG1 . BRD4-driven oncogenes promote increased tumor cells proliferation, genetic instability, epithelial-mesenchymal transition, metastasis and chemoresistance. Ablation of BRD4 activity can be successfully achieved with bromodomain inhibitors (BETi) and degraders, and it has been applied in pre-clinical and clinical settings. Inhibition of BRD4 function has an effective anti-cancer effect, reducing tumor growth whether ablated by single agents or in combination with other drugs. When combined with standard chemotherapy, BETi are capable of sensitizing highly resistant ovarian cancer cell lines to platinum drugs. Despite the evidence that BRD4 amplification in ovarian cancer contributes to poor patient prognosis, little is known about the specific mechanisms by which BRD4 drives tumor progression. In addition, newly emerging data revealed that BRD4 isoforms exhibit contradicting functions in cancer. Therefore, it is paramount to expand studies elucidating distinct roles of BRD4-L and BRD4-S in HGSOC, which has important implications on development of therapeutic approaches targeting BRD4.
Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21
Authors: Alessandro Tubita, Zoe Lombardi, Ignazia Tusa, Azzurra Lazzeretti, Giovanna Sgrignani, Dimitri Papini, Alessio Menconi, Sinforosa Gagliardi, Matteo Lulli, Persio Dello Sbarba, Azucena Esparís-Ogando, Atanasio Pandiella, Barbara Stecca, Elisabetta Rovida
Journal: Cancer Research (2021)

Melanoma is the deadliest skin cancer with a very poor prognosis in advanced stages. Although targeted and immune therapies have improved survival, not all patients benefit from these treatments. The mitogen-activated protein kinase ERK5 supports the growth of melanoma cells in vitro and in vivo. However, ERK5 inhibition results in cell-cycle arrest rather than appreciable apoptosis. To clarify the role of ERK5 in melanoma growth, we performed transcriptomic analyses following ERK5 knockdown in melanoma cells expressing BRAFV600E and found that cellular senescence was among the most affected processes. In melanoma cells expressing either wild-type or mutant (V600E) BRAF, both genetic and pharmacologic inhibition of ERK5 elicited cellular senescence, as observed by a marked increase in senescence-associated β-galactosidase activity and p21 expression. In addition, depletion of ERK5 from melanoma cells resulted in increased levels of CXCL1, CXCL8, and CCL20, proteins typically involved in the senescence-associated secretory phenotype. Knockdown of p21 suppressed the induction of cellular senescence by ERK5 blockade, pointing to p21 as a key mediator of this process. In vivo, ERK5 knockdown or inhibition with XMD8-92 in melanoma xenografts promoted cellular senescence. Based on these results, small-molecule compounds targeting ERK5 constitute a rational series of prosenescence drugs that may be exploited for melanoma treatment. SIGNIFICANCE: This study shows that targeting ERK5 induces p21-mediated cellular senescence in melanoma, identifying a prosenescence effect of ERK5 inhibitors that may be exploited for melanoma treatment.
Abstract 14545: Prevalence of Medication Non-Adherence via Therapeutic Drug Monitoring in Patients With Uncontrolled Hypertension Treated at a Safety Net Hospital
Authors: David Osula
Journal: Circulation (2021)

Background: Medication nonadherence presents one of the greatest challenges to hypertension management. Previous studies from our group have shown therapeutic drug monitoring (TDM), biochemical monitoring of drug levels, is more accurate than self-report, detailed questionnaires, or prescription fill rate in detecting nonadherence. Prior studies have also shown a prevalence of nonadherence from 45% to 80% among insured patients with uncontrolled hypertension despite having been prescribed a multi-drug regimen. Previous studies have not assessed adherence to antihypertensive drugs in a safety net population by TDM. Methods: We performed a cross-sectional study in patients with uncontrolled hypertension in the primary care Internal Medicine and Cardiology Clinics at Parkland Health&amp; Hospital System (PHHS). Patients with BP of ≥130/80 mmHg, prescribed ≥2 antihypertensive medications, and self-reporting medication adherence were enrolled after informed consent. Plasma samples were obtained for measurement of 44 cardiovascular drugs using liquid chromatography mass spectrometry. Results: Among 77 patients with uncontrolled hypertension (57% female, 65% Black, 12% Hispanic), 13 (17%) were nonadherent to at least one anti-hypertensive drug by TDM. The adherent and nonadherent groups had similar systolic (146±13 vs 148±18, p=0.67) and diastolic (83±9 vs 88±10 mmHg, p=0.13) BP. All patients had either medical insurance or some form of prescription financial assistance. Sixty two patients had insurance, while 15 had prescription financial assistance. Nonadherence rates for patients on financial assistance programs did not significantly differ from patients with medical insurance (13% vs 18%, p&gt;0.999). Conclusions: We found a surprisingly low prevalence of anti-hypertensive medication nonadherence in this uncontrolled hypertension population despite many barriers to treatment. Our study suggests a lesser role of medication nonadherence in uncontrolled hypertension in the safety net population.